Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention | RxWiki

Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention

Overview[ - collapse ][ - ]

Purpose	In Protocol #2, we will select 30 obese pubertal and 30 obese prepubertal subjects with an abnormal cytokine profile (i.e. fibrinogen and/or hsCRP concentration greater than or equal to 2 Standard Deviations (SD) above the mean established in our lab for lean controls in Protocol #1). They will be randomly assigned to either lifestyle intervention (diet/exercise) or diet/exercise plus metformin for 6 months. After the 6 month evaluation the subjects will cross over the treatment arms, i.e., those that were doing diet/exercise intervention only will add metformin, those that were doing the diet/exercise plus metformin will discontinue the metformin and continue with diet/exercise changes only. Intrahepatic fat contents will be measured as well. The investigators hypothesize that obese children in these age groups will have increased cardiovascular risk related to their obese state before reaching the currently defined criteria of metabolic syndrome. The investigators hypothesize that these cardiovascular risks can be reduced with lifestyle and drug interventions.
Condition	Obesity
Intervention	Drug: Metformin Behavioral: Dietary modification with caloric restriction Behavioral: Establishment of exercise protocol
Phase	N/A
Sponsor	Nemours Children's Clinic
Responsible Party	Nemours Children's Clinic
ClinicalTrials.gov Identifier	NCT00139477
First Received	August 29, 2005
Last Updated	October 21, 2012
Last verified	October 2012

Tracking Information[ + expand ][ + ]

First Received Date	August 29, 2005
Last Updated Date	October 21, 2012
Start Date	November 2003
Estimated Primary Completion Date	September 2011
Current Primary Outcome Measures	Protocol #1: Serum Marker Levels Between Obese and Lean Children [Time Frame: Screening Visit] [Designated as safety issue: No]This outcome measure is from Protocol #1 (a cross-sectional study); results are not posted. Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at 6 Months [Time Frame: Baseline and 6 months] [Designated as safety issue: No]Value at 6 months minus value at baseline. HsCRP is an acute phase protein which is a sensitive marker for systemic inflammation. HsCRP concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA), with an hsCRP lower sensitivity of 0.156 mg/L. Change From Baseline in Fibrinogen at 6 Months [Time Frame: Baseline and 6 months] [Designated as safety issue: No]Value at 6 months minus value at baseline. Fibrinogen is a hepatic-derived factor directly involved in clotting and in the viscosity characteristics of blood flow. It binds to platelets and contributes to their aggregation, promotes fibrin formation and is also an acute phase reactant that is increased in inflammatory states. Fibrinogen concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA). Change From Baseline in Interleukin 6 (IL-6) at 6 Months [Time Frame: Baseline and 6 months] [Designated as safety issue: No]Value at 6 months minus value at baseline. IL-6 is a pro-inflammatory cytokine thought to produce a state of low-grade inflammation in obese individuals. IL-6 stimulates hepatic production of C-reactive protein (CRP), an acute phase protein which is a sensitive marker for systemic inflammation. IL-6 was measured by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA). Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at 6 Months [Time Frame: Baseline and 6 months] [Designated as safety issue: No]Value at 6 months minus value at baseline. PAI-1 is the primary physiological inhibitor of fibrinolysis and proteolysis. High PAI-1 levels have been linked to thrombosis and fibrosis, insulin resistance and obesity. PAI-1 was measured by ELISA (American Diagnostica, Stamford, CT, USA).
Current Secondary Outcome Measures	Not Provided

Descriptive Information[ + expand ][ + ]

Brief Title	Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention
Official Title	Understanding the Effects of Therapeutic Intervention on Cardiovascular Risk Markers, Insulin Resistance, and Intra-Hepatic Fat Contents in Obese Children at High Risk for the Metabolic Syndrome.
Brief Summary	In Protocol #2, we will select 30 obese pubertal and 30 obese prepubertal subjects with an abnormal cytokine profile (i.e. fibrinogen and/or hsCRP concentration greater than or equal to 2 Standard Deviations (SD) above the mean established in our lab for lean controls in Protocol #1). They will be randomly assigned to either lifestyle intervention (diet/exercise) or diet/exercise plus metformin for 6 months. After the 6 month evaluation the subjects will cross over the treatment arms, i.e., those that were doing diet/exercise intervention only will add metformin, those that were doing the diet/exercise plus metformin will discontinue the metformin and continue with diet/exercise changes only. Intrahepatic fat contents will be measured as well. The investigators hypothesize that obese children in these age groups will have increased cardiovascular risk related to their obese state before reaching the currently defined criteria of metabolic syndrome. The investigators hypothesize that these cardiovascular risks can be reduced with lifestyle and drug interventions.
Detailed Description	Not Provided
Study Type	Interventional
Study Phase	N/A
Study Design	Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Condition	Obesity
Intervention	Drug: Metformin Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated. Behavioral: Dietary modification with caloric restriction The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry. Behavioral: Establishment of exercise protocol Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
Study Arm (s)	Experimental: Diet/Exercise only, then Diet/Exercise plus Metformin Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period). Active Comparator: Diet/Exercise plus Metformin, then Diet/Exercise only Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).

Recruitment Information[ + expand ][ + ]

Recruitment Status	Completed
Estimated Enrollment	66
Estimated Completion Date	September 2011
Estimated Primary Completion Date	May 2009
Eligibility Criteria	Inclusion Criteria: - Ages 7-18 years. - Greater than the 95th percentile body mass index for their age and gender. - Children are in Tanner Stage I or IV or V. - Normal Blood Pressure. - Normal fasting glucose. - Normal lipids. - Menstruating girls must have completed their most recent period at least 2 weeks prior to blood draw. - No recent illness, no chronic illnesses, no routine medications, no smoking or alcohol intake. - Must pass the screening test done in Protocol #1. - Must have higher values than normal for certain blood tests related to heart disease that were measured in Protocol #1. Exclusion Criteria: - Chronic active illnesses. - Recent illnesses. - Use of routine medications, vitamins, herbal remedies, oral contraceptive pills, or other over the counter medications within 4 weeks of blood draw. - History of recent or chronic smoking. - Currently pregnant. - Impaired fasting glucose. - Dyslipidemia. - Actively in puberty. - Weight greater than 300 pounds. - Metal in the abdomen. - History of being overweight greater than 5 years.
Gender	Both
Ages	7 Years
Accepts Healthy Volunteers	Accepts Healthy Volunteers
Contacts	Not Provided
Location Countries	United States

Administrative Information[ + expand ][ + ]

NCT Number	NCT00139477
Other Study ID Numbers	04-032
Has Data Monitoring Committee	Yes
Information Provided By	Nemours Children's Clinic
Study Sponsor	Nemours Children's Clinic
Collaborators	Thrasher Research Fund
Investigators	Principal Investigator: Nelly Mauras, MD Nemours Children's Clinic
Verification Date	October 2012

Locations[ + expand ][ + ]